CompletedPhase 3

Effect Levosimendan Administration on Postoperative NT-proBNP in Cardiac Risk Patients

Austria230 participantsStarted 2020-10-10

Plain-language summary

This is a prospective randomised trial investigating the effect of a preemptive administration of levosimendan on postoperative cardiac NT-proBNP concentrations.

Who can participate

Age range65 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Undergoing major surgery planned for more than 2 hours
✓. ≥ 65 years of age and ≤ 85 years of age
✓. Provide written informed consent AND
✓. Fulfill ≥ 2 of the following criteria (A-E)

What they're measuring

Postoperative maximum NT-proBNP concentration

Timeframe: First 5 Postoperative Days

Trial details

NCT IDNCT04329624

SponsorMedical University of Vienna

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-11-07

View on ClinicalTrials.gov More Cardiovascular Risk Factor trials